Purified limonin glucoside for prevention and treatment of chronic diseases

Abstract

One exemplary embodiment of the disclosure provides methods and compositions for treating a subject suffering from Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, type 2 diabetes, metabolic syndrome, cardiovascular disease, chronic kidney disease, and certain cancers, or a combination thereof, by administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject. In another exemplary embodiment, the disclosure provides methods and compositions for treating a subject suffering from elevated circulating concentrations of liver enzymes wherein the liver enzymes are selected from gamma glutamyl transferase, alanine amino transferase, alkaline phosphatase and complement fraction 3 or a combination thereof, the method comprising administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject wherein the treating results in a decreased circulating concentration of the liver enzymes.

What is claimed is: 
     
         1 . A method for treating a subject suffering from elevated circulating concentrations of liver enzymes, wherein the liver enzymes are gamma glutamyl transferase (GGT), alanine amino transferase (ALT), alkaline phosphatase (ALP) and complement fraction 3 (C3) the method comprising:
 (i) administering to the subject a therapeutically effective amount of purified limonin glucoside (LG) or a pharmaceutically acceptable salt thereof,   wherein the treating results in a decreased circulating concentration of all four of the liver enzymes, and   with the proviso that the subject is not otherwise in need of treatment with limonin glucoside.   
     
     
         2 . The method of  claim 1 , wherein the method is effective for treating a subject suffering from inflammation. 
     
     
         3 . The method of  claim 1 , wherein the daily dose of (LG) or a pharmaceutically acceptable salt thereof is about 0.25-19.0 g/day. 
     
     
         4 . The method of  claim 3 , wherein the dose is 0.5 gram per day. 
     
     
         5 . The method of  claim 1 , wherein the purified limonin glucoside or a pharmaceutically acceptable salt thereof, is administered at a frequency of 4 or less times per day. 
     
     
         6 . The method of  claim 5 , wherein the purified limonin glucoside or a pharmaceutically acceptable salt thereof, is administered two times per day. 
     
     
         7 . The method of  claim 1 , wherein the purified limonin glucoside or a pharmaceutically acceptable salt thereof, is administered orally. 
     
     
         8 . A method for treating a subject suffering from inflammation, the method comprising:
 (i) administering to the subject a therapeutically effective amount of purified limonin glucoside (LG) or a pharmaceutically acceptable salt thereof, wherein the treating results in decreased inflammation, and   with the proviso that the subject is not otherwise in need of treatment with limonin glucoside.   
     
     
         9 . The method of  claim 8 , wherein the daily dose of (LG) or a pharmaceutically acceptable salt thereof is about 0.25-19.0 g/day. 
     
     
         10 . The method of  claim 9 , wherein the dose is 0.5 gram per day. 
     
     
         11 . The method of  claim 8 , wherein the purified limonin glucoside or a pharmaceutically acceptable salt thereof, is administered at a frequency of 4 or less times per day. 
     
     
         12 . The method of  claim 11 , wherein the purified limonin glucoside or a pharmaceutically acceptable salt thereof, is administered two times per day. 
     
     
         13 . The method of  claim 8 , wherein the purified limonin glucoside or a pharmaceutically acceptable salt thereof, is administered orally.